PubMed | Yokohama Sakae Kyosai Hospital Yokohama, Yokohama Minami Kyosai Hospital Yokohama, Kanagawa Cardiovascular and Respiratory Center Yokohama, Cardiocore and 4 more.
Type: Journal Article | Journal: American journal of cardiovascular disease | Year: 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated anti-inflammatory and anti-atherogenic effects in an animal model. However, the clinical usefulness of DPP-4 inhibitors, particularly its effects on coronary atherosclerosis, has not been evaluated thus far. Therefore, in this study, we evaluated the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis using integrated backscatter (IB)-intravascular ultrasound (IVUS) in patients with type 2 diabetes. This trial was a prospective, open-labeled, randomized, multicenter study. Twenty-eight patients with type 2 diabetes who underwent elective percutaneous coronary intervention (PCI) were randomly assigned to either the sitagliptin group (group S) or the control group (group C). Non-PCI lesions were evaluated using IB-IVUS at the time of PCI and at the 48-week follow-up. The primary endpoint was the percentage change in plaque volume measured using grayscale IVUS, and the secondary endpoint was changes in plaque composition evaluated using IB-IVUS. Grayscale IVUS analysis demonstrated that plaque volume tended to decrease in both groups (group S: -1.78.5%; group C: -3.212.2%), but a between-group difference was not observed. A decrease in the lipid plaque volume (group S: from 200.1116.2 to 179.8121.0 mm